VRNA Vikas Sinha sells $1.5M worth of shares
May 23, 2025, 4:35 AM
0.00%
What does VRNA do
Verona Pharma Plc develops therapeutics for respiratory diseases, focusing on its investigational inhaled drug, ensifentrine, for chronic obstructive pulmonary disease (COPD). Two additional formulations of ensifentrine are in Phase II development.
Vikas Sinha sold 160,000 shares of VRNA on 20 May at $9.39 per share, worth a total of $1.5M. They now own 74,440 VRNA shares, or a 68% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.